Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
The mechanism of abnormal iron accumulation in the substantia nigra (SN) pars compacta of patients with Parkinson's disease (PD) is unknown. To explore this question, we made a hemiparkinsonism model in monkeys by injecting 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the caudate or putamen on one side, and compared iron content in the SN and other basal ganglia structures by histochemistry. The injected side, especially the SN pars compacta, showed a marked increase in iron staining. Our study indicates that an injury to the nigrostriatal system by MPTP injection can induce iron accumulation in the SN.
Mochizuki
H
H
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Imai
H
H
Endo
K
K
Yokomizo
K
K
Murata
Y
Y
Hattori
N
N
Mizuno
Y
Y
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage; D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002421:Caudate Nucleus / Q000187:drug effects / Q000473:pathology; D007501:Iron / Q000378:metabolism*; D020267:MPTP Poisoning; D008252:Macaca fascicularis; D008297:Male; D008845:Microinjections; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D007501:Iron